Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03301896 |
| Title | Phase I/Ib Study of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Novartis Pharmaceuticals |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | ITA | ESP | DEU | BEL |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| UCLA | Los Angeles | California | 90095 | United States | Details | |
| MD Anderson Cancer Center | Houston | Texas | 77030 | United States | Details | |
| Novartis Investigative Site | Wilrijk | 2610 | Belgium | Details | ||
| Novartis Investigative Site | Ulm | 89081 | Germany | Details | ||
| Novartis Investigative Site | Milano | MI | 20141 | Italy | Details | |
| Novartis Investigative Site | Chuo ku | Tokyo | 104 0045 | Japan | Details | |
| Novartis Investigative Site | Seoul | 03080 | Korea, Republic of | Details | ||
| Novartis Investigative Site | Barcelona | Catalunya | 08035 | Spain | Details | |
| Novartis Investigative Site | Madrid | 28009 | Spain | Details |